A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis

Cancer Prevention Research

Volumn 4, Issue 5, 2011, Pages 655-665

  Burn, John ^a   Bishop, D Timothy ^b   Chapman, Pamela D ^a   Elliott, Faye ^b   Bertario, Lucio ⁱ   Dunlop, Malcolm G ^c   Eccles, Diana ^d   Ellis, Anthony ^e   Evans, D Gareth ^f   Fodde, Riccardo ^j   Maher, Eamonn R ^g   Möslein, Gabriela ^l   Vasen, Hans F A ^k   Coaker, Julie ^a   Phillips, Robin K S ^h   Bülow, Steffen ^m   Mathers, John C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d PRINCESS ANNE HOSPITAL   (United Kingdom)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f ST MARY S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h ST MARK S HOSPITAL   (United Kingdom)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l St Josef Hospital   (Germany)

^m HVIDOVRE HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; RESISTANT STARCH; STARCH; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ADOLESCENT; ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CHILD; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COLORECTAL ADENOMA; CONTROLLED STUDY; CRYPT CELL; DISEASE COURSE; ENDOSCOPY; FACTORIAL ANALYSIS; FAMILIAL ADENOMATOUS POLYPOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POLYPECTOMY; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM POLYP; RISK ASSESSMENT; RISK REDUCTION; SCHOOL CHILD; SIGMOID;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERNATIONAL AGENCIES; MALE; PROGNOSIS; RECTUM; STARCH; YOUNG ADULT;

EID: 79955832527     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0106     Document Type: Article

References (34)

1. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
2. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010;59:1670-9.
3. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. (Pubitemid 36297996)
4. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
5. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36. (Pubitemid 36929412)
6. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38. (Pubitemid 350309319)
7. Young G, Le Leu RK. Resistant starch and colorectal cancer. J AOAC Int 2004;87:775-86.
8. Cassidy A, Bingham SA, Cummings JH. Starch intake and colorectal cancer risk: an international comparison. Br J Cancer 1994;69:937-42. (Pubitemid 24140679)
9. Asp NG, van Amelsvoort JM, Hautvast JG. Nutritional implications of resistant starch. Nutr Res Rev 1996;9:1-31. (Pubitemid 126493261)
10. Scheppach W, Fabian C, Sachs M, Kasper H. Effect of starch malabsorption on fecal short-chain fatty acidexcretion of man. Scand J Gastroenterol 1988;23:755-9.
11. Hylla S, Gostner A, Dusel G, Anger H, Bartram HP, Christl SU, et al. Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. Am J Clin Nutr 1998;67:136-42. (Pubitemid 28037638)
12. Grubben MJ, van den Braak CC, Essenberg M, Olthof M, Tangerman A, Katan MB, et al. Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas. Dig Dis Sci 2001;46:750-6. (Pubitemid 32373092)
13. D'Argenio G, Cosenza V, Delle Cave M, Iovino P, Delle Valle N, Lombardi G, et al. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology 1996;110:1727-34. (Pubitemid 26169209)
14. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993;55:498-505. (Pubitemid 23300605)
15. Heerdt B, Houston M, Augenlicht L. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 1994;54:3288-93.
16. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression 10.1136/gut.46.4.507. Gut 2000;46:507-14. (Pubitemid 30305815)
17. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561-72. (Pubitemid 32103641)
18. Williams EA, Coxhead JM, Mathers J. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc Nutr Soc 2003;62:107-15. (Pubitemid 36569816)
19. van Munster IP, Tangerman A, Nagengast FM. Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. Dig Dis Sci 1994;39:834-42. (Pubitemid 24141790)
20. Grubben MJ, van den Braak CC, Essenberg M, Olthof M, Tangerman A, Katan MB, et al. Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: a controlled trial. Dig Dis Sci 2001;46:750-6. (Pubitemid 32373092)
21. Goodlad RA, Levi S, Lee CY, Mandir N, Hodgson H, Wright NA. Morphometry and cell proliferation in endoscopic biopsies: evaluation of a technique. Gastroenterology 1991;101:1235-41.
22. Mills SJ, Mathers JC, Chapman PD, Burn J, Gunn A. Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. Gut 2001;48:41-6. (Pubitemid 32042640)
23. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
24. Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008;359:2567-78.
25. Burn J, Gerdes AM, Mecklin J-P, et al. Aspirin prevents cancer in Lynch syndrome. Eur J Cancer Suppl 2009;7:320-21.
26. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007;146:361-4.
27. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003;361:1496-501. (Pubitemid 36566339)
28. Bingham S. The fibre-folate debate in colo-rectal cancer. Proc Nutr Soc 2006;65:19-23. (Pubitemid 43259980)
29. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
30. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 2009;2:310-21.
31. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52. (Pubitemid 30419089)
32. Stark LA, Dunlop MG. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol Cell Biol 2005;25:5985-6004.
33. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism 10.1096/fj.06-5987com. FASEB J 2006;20:2009-16. (Pubitemid 44953901)
34. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.